Table 1.
Summary of HIV RNA Shedders (N=3)
| Parent study |
Study week |
ART regimen |
Last missed Doses During study |
Genital HIV RNA (copies/ml) |
Plasma HIV RNA* (copies/ml) |
CMV DNA (copies/ml) |
HSV DNA (copies/ml) |
Gonorrhea RNA |
Chlamydia RNA |
|---|---|---|---|---|---|---|---|---|---|
| ASPIRE #1 | 48 | RPV/TDF/FTC | 1–2 weeks | 42 | 179 | Not detected | Not detected | Not detected | Not detected |
| ASPIRE #2** |
36 | DTG+3TC | > 3 months | 488 | <20 | 314607 | Not detected | Not detected | Not detected |
| 48 | DTG+3TC | Never | 79 | 31 | 86090 | Not detected | Not detected | Not detected | |
| A5353 | 24 | DTG+3TC | Never | 48 | <40 | NA*** | NA*** | Not detected | Not detected |
Legend: RPV: Rilpivirine, TDF: Tenofovir, FTC: Emtricitabine, DTG: Dolutegravir, 3TC: Lamivudine. NA: Not Available.
*
Plasma HIV RNA collected at the same time as genital HIV RNA shedding
**
ASPIRE participant #2 had detectable HIV RNA at two consecutive time-points (weeks 36 and 48)
***
Genital HSV and CMV testing could not be completed in one participant with HIV genital shedding because there was not enough seminal plasma to perform this analysis.